JP2011501962A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2011501962A5 JP2011501962A5 JP2010532219A JP2010532219A JP2011501962A5 JP 2011501962 A5 JP2011501962 A5 JP 2011501962A5 JP 2010532219 A JP2010532219 A JP 2010532219A JP 2010532219 A JP2010532219 A JP 2010532219A JP 2011501962 A5 JP2011501962 A5 JP 2011501962A5
- Authority
- JP
- Japan
- Prior art keywords
- compound according
- nucleobase
- modified
- compound
- liver cancer
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 150000001875 compounds Chemical class 0.000 claims 19
- 201000007270 liver cancer Diseases 0.000 claims 6
- 208000014018 liver neoplasm Diseases 0.000 claims 6
- 239000002777 nucleoside Substances 0.000 claims 4
- 210000002966 serum Anatomy 0.000 claims 4
- 108091034117 Oligonucleotide Proteins 0.000 claims 3
- 150000003833 nucleoside derivatives Chemical class 0.000 claims 3
- AOJJSUZBOXZQNB-TZSSRYMLSA-N Doxorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-TZSSRYMLSA-N 0.000 claims 2
- 206010028980 Neoplasm Diseases 0.000 claims 2
- 108010063628 acarboxyprothrombin Proteins 0.000 claims 2
- 102000013529 alpha-Fetoproteins Human genes 0.000 claims 2
- 108010026331 alpha-Fetoproteins Proteins 0.000 claims 2
- 239000002246 antineoplastic agent Substances 0.000 claims 2
- 229940127089 cytotoxic agent Drugs 0.000 claims 2
- 230000004048 modification Effects 0.000 claims 2
- 238000012986 modification Methods 0.000 claims 2
- 230000004083 survival effect Effects 0.000 claims 2
- KVGZZAHHUNAVKZ-UHFFFAOYSA-N 1,4-Dioxin Chemical group O1C=COC=C1 KVGZZAHHUNAVKZ-UHFFFAOYSA-N 0.000 claims 1
- AOJJSUZBOXZQNB-VTZDEGQISA-N 4'-epidoxorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-VTZDEGQISA-N 0.000 claims 1
- LRSASMSXMSNRBT-UHFFFAOYSA-N 5-methylcytosine Chemical group CC1=CNC(=O)N=C1N LRSASMSXMSNRBT-UHFFFAOYSA-N 0.000 claims 1
- MLDQJTXFUGDVEO-UHFFFAOYSA-N BAY-43-9006 Chemical compound C1=NC(C(=O)NC)=CC(OC=2C=CC(NC(=O)NC=3C=C(C(Cl)=CC=3)C(F)(F)F)=CC=2)=C1 MLDQJTXFUGDVEO-UHFFFAOYSA-N 0.000 claims 1
- HTIJFSOGRVMCQR-UHFFFAOYSA-N Epirubicin Natural products COc1cccc2C(=O)c3c(O)c4CC(O)(CC(OC5CC(N)C(=O)C(C)O5)c4c(O)c3C(=O)c12)C(=O)CO HTIJFSOGRVMCQR-UHFFFAOYSA-N 0.000 claims 1
- GHASVSINZRGABV-UHFFFAOYSA-N Fluorouracil Chemical compound FC1=CNC(=O)NC1=O GHASVSINZRGABV-UHFFFAOYSA-N 0.000 claims 1
- 239000005511 L01XE05 - Sorafenib Substances 0.000 claims 1
- NWIBSHFKIJFRCO-WUDYKRTCSA-N Mytomycin Chemical compound C1N2C(C(C(C)=C(N)C3=O)=O)=C3[C@@H](COC(N)=O)[C@@]2(OC)[C@@H]2[C@H]1N2 NWIBSHFKIJFRCO-WUDYKRTCSA-N 0.000 claims 1
- 238000011374 additional therapy Methods 0.000 claims 1
- 125000002619 bicyclic group Chemical group 0.000 claims 1
- 229960004562 carboplatin Drugs 0.000 claims 1
- 190000008236 carboplatin Chemical compound 0.000 claims 1
- 230000007423 decrease Effects 0.000 claims 1
- 229960004679 doxorubicin Drugs 0.000 claims 1
- 229960001904 epirubicin Drugs 0.000 claims 1
- VJJPUSNTGOMMGY-MRVIYFEKSA-N etoposide Chemical compound COC1=C(O)C(OC)=CC([C@@H]2C3=CC=4OCOC=4C=C3[C@@H](O[C@H]3[C@@H]([C@@H](O)[C@@H]4O[C@H](C)OC[C@H]4O3)O)[C@@H]3[C@@H]2C(OC3)=O)=C1 VJJPUSNTGOMMGY-MRVIYFEKSA-N 0.000 claims 1
- 229960005420 etoposide Drugs 0.000 claims 1
- 229960002949 fluorouracil Drugs 0.000 claims 1
- SDUQYLNIPVEERB-QPPQHZFASA-N gemcitabine Chemical compound O=C1N=C(N)C=CN1[C@H]1C(F)(F)[C@H](O)[C@@H](CO)O1 SDUQYLNIPVEERB-QPPQHZFASA-N 0.000 claims 1
- 229960005277 gemcitabine Drugs 0.000 claims 1
- 206010073071 hepatocellular carcinoma Diseases 0.000 claims 1
- 231100000844 hepatocellular carcinoma Toxicity 0.000 claims 1
- 229960004768 irinotecan Drugs 0.000 claims 1
- UWKQSNNFCGGAFS-XIFFEERXSA-N irinotecan Chemical compound C1=C2C(CC)=C3CN(C(C4=C([C@@](C(=O)OC4)(O)CC)C=4)=O)C=4C3=NC2=CC=C1OC(=O)N(CC1)CCC1N1CCCCC1 UWKQSNNFCGGAFS-XIFFEERXSA-N 0.000 claims 1
- 238000000034 method Methods 0.000 claims 1
- 125000003835 nucleoside group Chemical group 0.000 claims 1
- DWAFYCQODLXJNR-BNTLRKBRSA-L oxaliplatin Chemical compound O1C(=O)C(=O)O[Pt]11N[C@@H]2CCCC[C@H]2N1 DWAFYCQODLXJNR-BNTLRKBRSA-L 0.000 claims 1
- 229960001756 oxaliplatin Drugs 0.000 claims 1
- 229960003787 sorafenib Drugs 0.000 claims 1
- 238000002560 therapeutic procedure Methods 0.000 claims 1
- RYYWUUFWQRZTIU-UHFFFAOYSA-K thiophosphate Chemical compound [O-]P([O-])([O-])=S RYYWUUFWQRZTIU-UHFFFAOYSA-K 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US98323107P | 2007-10-29 | 2007-10-29 | |
| US60/983,231 | 2007-10-29 | ||
| PCT/US2008/081645 WO2009058907A2 (en) | 2007-10-29 | 2008-10-29 | Targeting micrornas for the treatment of liver cancer |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2011501962A JP2011501962A (ja) | 2011-01-20 |
| JP2011501962A5 true JP2011501962A5 (enExample) | 2012-05-10 |
| JP5535076B2 JP5535076B2 (ja) | 2014-07-02 |
Family
ID=40524369
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2010532219A Active JP5535076B2 (ja) | 2007-10-29 | 2008-10-29 | 肝臓癌を治療するための標的化ミクロｒｎａ |
Country Status (8)
| Country | Link |
|---|---|
| US (6) | US8211867B2 (enExample) |
| EP (1) | EP2217248B1 (enExample) |
| JP (1) | JP5535076B2 (enExample) |
| CN (1) | CN101980712B (enExample) |
| AU (1) | AU2008318778B2 (enExample) |
| CA (1) | CA2704043C (enExample) |
| IL (1) | IL205307A (enExample) |
| WO (1) | WO2009058907A2 (enExample) |
Families Citing this family (61)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2808389A1 (en) | 2004-11-12 | 2014-12-03 | Asuragen, Inc. | Methods and compositions involving MIRNA and MIRNA inhibitor molecules |
| US8252756B2 (en) | 2005-06-14 | 2012-08-28 | Northwestern University | Nucleic acid functionalized nanoparticles for therapeutic applications |
| ES2508893T3 (es) | 2006-01-05 | 2014-10-16 | The Ohio State University Research Foundation | Métodos basados en microARN para el diagnóstico de cánceres de estómago |
| EP2371971B1 (en) | 2006-03-20 | 2013-11-27 | The Ohio State University Research Foundation | Microrna fingerprints during human megakaryocytopoiesis |
| CA2691066C (en) | 2007-02-09 | 2018-07-31 | Northwestern University | Particles for detecting intracellular targets |
| EP2173908B1 (en) | 2007-08-03 | 2016-01-06 | The Ohio State University Research Foundation | Ultraconserved regions encoding ncrnas |
| EP2217248B1 (en) | 2007-10-29 | 2016-11-30 | Regulus Therapeutics Inc. | Targeting micrornas for the treatment of liver cancer |
| US20110034538A1 (en) * | 2008-02-28 | 2011-02-10 | The Ohio State University Research Foundation | MicroRNA-Based Methods and Compositions for the Diagnosis, Prognosis and Treatment of Gastric Cancer |
| EP2990487A1 (en) | 2008-05-08 | 2016-03-02 | Asuragen, INC. | Compositions and methods related to mirna modulation of neovascularization or angiogenesis |
| US20100233270A1 (en) | 2009-01-08 | 2010-09-16 | Northwestern University | Delivery of Oligonucleotide-Functionalized Nanoparticles |
| US20120277283A1 (en) * | 2009-08-04 | 2012-11-01 | Mirkin Chad A | Localized Delivery of Gold Nanoparticles for Therapeutic and Diagnostic Applications |
| AU2010321555B2 (en) | 2009-11-23 | 2015-10-15 | The Ohio State University | Materials and methods useful for affecting tumor cell growth, migration and invasion |
| CA2781618A1 (en) * | 2009-11-25 | 2011-06-03 | Elitech Holding B.V. | Minor groove binder (mgb)-oligonucleotide mirna antagonists |
| WO2011076141A1 (en) * | 2009-12-24 | 2011-06-30 | Fudan University | Diagnostic kits comprising microrna biomarkers and methods for diagnosis of hepatocellular cancer |
| CN101831427B (zh) * | 2010-04-01 | 2012-07-18 | 清华大学深圳研究生院 | 一种预防肿瘤复发和抑制肿瘤生长的寡聚核酸及其应用 |
| CA2801342A1 (en) | 2010-06-04 | 2011-12-08 | Eric N. Olson | Regulation of metabolism by mir-378 |
| EP2594643B1 (en) * | 2010-07-12 | 2017-04-12 | National University Corporation Tottori University | Method for producing novel hipsc by means of sirna introduction |
| CN103648505B (zh) | 2010-11-12 | 2016-09-28 | 俄亥俄州立大学研究基金会 | 与微rna-21、错配修复和结肠直肠癌相关的材料和方法 |
| AU2011329066B2 (en) | 2010-11-15 | 2017-03-09 | The Ohio State University Research Foundation | Controlled release mucoadhesive systems |
| CN102140471B (zh) * | 2011-01-10 | 2013-11-20 | 清华大学深圳研究生院 | 一种抑制肿瘤生长的寡聚核酸及其应用 |
| CN102125696B (zh) * | 2011-01-11 | 2013-06-12 | 清华大学深圳研究生院 | 抑制肿瘤生长及血管生成的寡聚核酸组合物及其应用 |
| CN103476931A (zh) | 2011-02-03 | 2013-12-25 | 米尔纳医疗股份有限公司 | Mir-34的合成模拟物 |
| CN103459598B (zh) | 2011-02-03 | 2016-08-10 | 米尔纳医疗股份有限公司 | Mir-124的合成模拟物 |
| US8420617B2 (en) | 2011-03-11 | 2013-04-16 | Biocell Laboratories | Multiantivirus compound, composition and method for treatment of virus diseases |
| CN102178959B (zh) * | 2011-03-15 | 2013-10-23 | 清华大学深圳研究生院 | 抑制肺转移肿瘤生长的siRNA及其寡聚核酸组合与应用 |
| WO2012145374A1 (en) * | 2011-04-19 | 2012-10-26 | Regulus Therapeutics Inc. | TARGETING miR-378 FAMILY MEMBERS FOR THE TREATMENT OF METABOLIC DISORDERS |
| CA3165397A1 (en) * | 2011-04-25 | 2012-11-01 | Sanofi | Microrna compounds and methods for modulating mir-21 activity |
| JP6669430B2 (ja) * | 2011-05-06 | 2020-03-18 | ニユー・イングランド・バイオレイブス・インコーポレイテツド | ライゲーションの促進 |
| CA2847698C (en) | 2011-09-14 | 2020-09-01 | Northwestern University | Nanoconjugates able to cross the blood-brain barrier |
| WO2013056217A1 (en) | 2011-10-14 | 2013-04-18 | The Ohio State University | Methods and materials related to ovarian cancer |
| CN104619353A (zh) * | 2011-12-13 | 2015-05-13 | 俄亥俄州国家创新基金会 | 与miR-21和miR-29a相关的方法和组合物、外切体抑制和癌症转移 |
| WO2013110053A1 (en) | 2012-01-20 | 2013-07-25 | The Ohio State University | Breast cancer biomarker signatures for invasiveness and prognosis |
| CA2869639A1 (en) | 2012-04-25 | 2013-10-31 | Regulus Therapeutics Inc. | Microrna compounds and methods for modulating mir-21 activity |
| JP2014027898A (ja) * | 2012-07-31 | 2014-02-13 | Yamaguchi Univ | 肝細胞がん発症リスクの判定方法 |
| UA116639C2 (uk) | 2012-10-09 | 2018-04-25 | Рег'Юлес Терап'Ютікс Інк. | Способи лікування синдрому альпорта |
| WO2015061536A1 (en) | 2013-10-25 | 2015-04-30 | Regulus Therapeutics Inc. | Microrna compounds and methods for modulating mir-21 activity |
| JP6527516B2 (ja) | 2013-12-03 | 2019-06-05 | ノースウェスタン ユニバーシティ | リポソーム粒子、前述のものを作製する方法及びその使用 |
| ES2725948T3 (es) | 2014-06-04 | 2019-09-30 | Exicure Inc | Suministro multivalente de inmunomoduladores mediante ácidos nucleicos esféricos liposomales para aplicaciones profilácticas o terapéuticas |
| CA2968531A1 (en) | 2014-11-21 | 2016-05-26 | Northwestern University | The sequence-specific cellular uptake of spherical nucleic acid nanoparticle conjugates |
| EP3337900B1 (en) * | 2015-08-20 | 2021-04-07 | Asociación Centro de Investigación Cooperativa en Biociencias - CIC bioGUNE | Methods and compositions to treat liver diseases and conditions |
| EP3446515B1 (en) | 2016-04-20 | 2020-12-02 | Convida Wireless, LLC | System information provisioning |
| JP6837492B2 (ja) | 2016-04-20 | 2021-03-03 | コンヴィーダ ワイヤレス， エルエルシー | 新しい無線における物理チャネル |
| KR102175608B1 (ko) | 2016-04-20 | 2020-11-06 | 콘비다 와이어리스, 엘엘씨 | 구성가능한 기준 신호들 |
| US10271295B2 (en) | 2016-04-20 | 2019-04-23 | Convida Wireless, Llc | Downlink synchronization |
| CN109588057B (zh) | 2016-05-11 | 2021-09-07 | 康维达无线有限责任公司 | 一种经由通信电路连接到网络的方法和装置 |
| US10367620B2 (en) | 2016-06-15 | 2019-07-30 | Convida Wireless, Llc | Upload control signaling for new radio |
| CN109644089B (zh) | 2016-06-15 | 2022-04-26 | 康维达无线有限责任公司 | 用于新无线电的无许可上行链路传输 |
| EP3473049A1 (en) | 2016-06-15 | 2019-04-24 | Convida Wireless, LLC | Grant-less operations |
| KR20240006080A (ko) | 2016-08-11 | 2024-01-12 | 인터디지탈 패튼 홀딩스, 인크 | 뉴 라디오를 위한 유연한 프레임 구조에서의 빔포밍 스위핑 및 트레이닝 |
| WO2018039629A2 (en) | 2016-08-25 | 2018-03-01 | Northwestern University | Micellar spherical nucleic acids from thermoresponsive, traceless templates |
| US11584932B2 (en) | 2016-11-01 | 2023-02-21 | The Research Foundation For The State University Of New York | 5-halouracil-modified microRNAs and their use in the treatment of cancer |
| US11236337B2 (en) | 2016-11-01 | 2022-02-01 | The Research Foundation For The State University Of New York | 5-halouracil-modified microRNAs and their use in the treatment of cancer |
| CN109891772B (zh) | 2016-11-03 | 2022-10-04 | 康维达无线有限责任公司 | Nr中的帧结构 |
| EP3548005A4 (en) | 2016-11-29 | 2020-06-17 | Puretech Health LLC | Exosomes for delivery of therapeutic agents |
| US10767164B2 (en) | 2017-03-30 | 2020-09-08 | The Research Foundation For The State University Of New York | Microenvironments for self-assembly of islet organoids from stem cells differentiation |
| WO2018209270A1 (en) | 2017-05-11 | 2018-11-15 | Northwestern University | Adoptive cell therapy using spherical nucleic acids (snas) |
| CN119922729A (zh) | 2018-09-27 | 2025-05-02 | 交互数字专利控股公司 | 新无线电的未经许可的频谱中的子频带操作 |
| CN109880907A (zh) * | 2019-03-26 | 2019-06-14 | 中国人民解放军第八一医院 | 一种肝癌细胞侵袭转移的分子机制研究方法 |
| WO2021262919A2 (en) | 2020-06-26 | 2021-12-30 | The Research Foundation For The State University Of New York | 5-halouracil-modified micrornas and their use in the treatment of cancer |
| IL311734A (en) * | 2021-10-08 | 2024-05-01 | Regulus Therapeutics Inc | Methods and compositions for the treatment of polycystic kidney disease |
| WO2025104709A1 (en) * | 2023-11-17 | 2025-05-22 | Biorchestra Co., Ltd. | Microrna-378a-3p antisense oligonucleotides and uses thereof |
Family Cites Families (33)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2003070884A2 (en) * | 2002-02-20 | 2003-08-28 | Sirna Therapeutics, Inc. | RNA INTERFERENCE MEDIATED INHIBITION OF MDR P-GLYCOPROTEIN GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (siNA) |
| JP4334165B2 (ja) | 2001-07-13 | 2009-09-30 | コニカミノルタホールディングス株式会社 | 静電潜像現像用トナーと画像形成方法及び画像形成装置 |
| EP2428568B1 (en) * | 2001-09-28 | 2018-04-25 | Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. | Microrna molecules |
| JP4369691B2 (ja) | 2003-06-26 | 2009-11-25 | 株式会社Ｉｄｘ | マイクロ波化学反応装置 |
| EP2530157B1 (en) * | 2003-07-31 | 2016-09-28 | Regulus Therapeutics Inc. | Oligomeric compounds and compositions for use in modulation of miRNAs |
| WO2005014793A2 (en) * | 2003-08-07 | 2005-02-17 | Gene Logic, Inc. | Primary rat hepatocyte toxicity modeling |
| JP3959722B2 (ja) | 2003-10-15 | 2007-08-15 | 住友金属工業株式会社 | 線材コイルの冷却装置 |
| EP2295604B1 (en) | 2004-02-09 | 2015-04-08 | Thomas Jefferson University | Diagnosis and treatment of cancers with microRNA located in or near cancer-associated chromosomal features |
| US20050182005A1 (en) * | 2004-02-13 | 2005-08-18 | Tuschl Thomas H. | Anti-microRNA oligonucleotide molecules |
| US7888010B2 (en) * | 2004-05-28 | 2011-02-15 | Asuragen, Inc. | Methods and compositions involving microRNA |
| US7635563B2 (en) * | 2004-06-30 | 2009-12-22 | Massachusetts Institute Of Technology | High throughput methods relating to microRNA expression analysis |
| EP1791567B1 (en) * | 2004-08-10 | 2015-07-29 | Alnylam Pharmaceuticals Inc. | Chemically modified oligonucleotides |
| EP2808389A1 (en) | 2004-11-12 | 2014-12-03 | Asuragen, Inc. | Methods and compositions involving MIRNA and MIRNA inhibitor molecules |
| CN1800388A (zh) | 2005-01-07 | 2006-07-12 | 中国人民解放军军事医学科学院放射医学研究所 | 八种人源miRNA |
| EP1874936B1 (en) * | 2005-04-19 | 2013-10-30 | BASF Plant Science GmbH | Improved methods controlling gene expression |
| US20070065844A1 (en) * | 2005-06-08 | 2007-03-22 | Massachusetts Institute Of Technology | Solution-based methods for RNA expression profiling |
| JP2007073737A (ja) | 2005-09-07 | 2007-03-22 | Toyo Ink Mfg Co Ltd | 複数の導電性回路層を有するプリント配線板並びにその製造方法 |
| DE102005046385B4 (de) | 2005-09-28 | 2012-03-22 | Siemens Ag | Verfahren und Vorrichtung zur Nachbearbeitung eines 3D-Bilddatensatzes, insbesondere für die virtuelle Kolonographie |
| JP2007097429A (ja) * | 2005-09-30 | 2007-04-19 | Mitsubishi Rayon Co Ltd | ｎｏｎ−ｃｏｄｉｎｇＲＮＡの検出データ補正方法 |
| JP4483757B2 (ja) | 2005-09-30 | 2010-06-16 | セイコーエプソン株式会社 | 有機ｅｌ装置及び光学装置 |
| US20070092882A1 (en) * | 2005-10-21 | 2007-04-26 | Hui Wang | Analysis of microRNA |
| US20100286044A1 (en) * | 2005-12-29 | 2010-11-11 | Exiqon A/S | Detection of tissue origin of cancer |
| EP1984499B1 (en) * | 2006-01-27 | 2015-05-27 | Isis Pharmaceuticals, Inc. | Oligomeric compounds and compositions for the use in modulation of micrornas |
| US20080312099A1 (en) * | 2006-02-15 | 2008-12-18 | University Of Louisville Research Foundation, Inc. | Microarray, System, and Method for Detecting, Identifying, and Quantitating Micro-Rnas |
| US20100184209A1 (en) | 2006-02-17 | 2010-07-22 | Dharmacon, Inc. | Compositions and methods for inhibiting gene silencing by rna interference |
| WO2007112754A2 (en) * | 2006-04-03 | 2007-10-11 | Santaris Pharma A/S | Pharmaceutical compositions comprising anti-mirna antisense oligonucleotides |
| EP2369017B8 (en) * | 2006-07-13 | 2014-03-12 | The Ohio State University Research Foundation | Micro-RNA-based methods and compositions for the diagnosis and treatment of colon related diseases |
| US20080199961A1 (en) | 2006-08-25 | 2008-08-21 | Avi Biopharma, Inc. | ANTISENSE COMPOSITION AND METHOD FOR INHIBITION OF miRNA BIOGENESIS |
| WO2008054828A2 (en) * | 2006-11-01 | 2008-05-08 | The Ohio State University Research Foundation | Microrna expression signature for predicting survival and metastases in hepatocellular carcinoma |
| WO2008073920A2 (en) * | 2006-12-08 | 2008-06-19 | Asuragen, Inc. | Mir-21 regulated genes and pathways as targets for therapeutic intervention |
| JP2009043353A (ja) | 2007-08-09 | 2009-02-26 | Pioneer Electronic Corp | タイトル付与装置、タイトル付与方法、タイトル付与プログラム、および記録媒体 |
| ES2406686T3 (es) | 2007-10-04 | 2013-06-07 | Santaris Pharma A/S | Micromirs |
| EP2217248B1 (en) | 2007-10-29 | 2016-11-30 | Regulus Therapeutics Inc. | Targeting micrornas for the treatment of liver cancer |
-
2008
- 2008-10-29 EP EP08844596.0A patent/EP2217248B1/en active Active
- 2008-10-29 CA CA2704043A patent/CA2704043C/en active Active
- 2008-10-29 AU AU2008318778A patent/AU2008318778B2/en active Active
- 2008-10-29 WO PCT/US2008/081645 patent/WO2009058907A2/en not_active Ceased
- 2008-10-29 JP JP2010532219A patent/JP5535076B2/ja active Active
- 2008-10-29 CN CN200880121316.9A patent/CN101980712B/zh active Active
- 2008-10-29 US US12/740,211 patent/US8211867B2/en active Active
-
2010
- 2010-04-25 IL IL205307A patent/IL205307A/en active IP Right Grant
-
2012
- 2012-05-25 US US13/481,105 patent/US8680067B2/en active Active
-
2014
- 2014-01-30 US US14/168,812 patent/US9150857B2/en active Active
-
2015
- 2015-08-24 US US14/833,889 patent/US9506062B2/en not_active Expired - Fee Related
-
2016
- 2016-10-26 US US15/334,422 patent/US9845470B2/en active Active
-
2017
- 2017-11-15 US US15/813,584 patent/US10301627B2/en active Active